SCHEMBL4818675

SCHEMBL4818675

[CH2]/C=C/c1cncc(C(=O)N(CC)CC)c1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RAF1 P04049 4/20 0.39
▸ HPGD P15428 8/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ LMNA P02545 3/20 0.38
▸ PKMYT1 Q99640 1/20 0.38
▸ HSP90AA1 P07900 5/20 0.38
▸ HSP90AB1 P08238 5/20 0.38
▸ RECQL P46063 1/20 0.38
▸ MAPT P10636 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MLYCD O95822 1/20 0.36
▸ CYP1A2 P05177 1/20 0.35
▸ BLM P54132 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820430 0.79 RAF1 (0.39) RAF1ALDH1A1PKMYT1MEN1KMT2A
SCHEMBL4810605 0.74 RAF1 (0.57) RAF1PKMYT1
SCHEMBL12677900 0.74 HPGD (0.57) HPGDTDP1ALDH1A1LMNAHSP90AA1
SCHEMBL4821799 0.74 POLB (0.56) HPGDTDP1MAPTKMT2ASMN1; SMN2
SCHEMBL27690353 0.73 HPGD (0.47) HPGDTDP1ALDH1A1LMNAHSP90AA1
SCHEMBL4819246 0.70 HTT (0.55) RAF1TDP1ALDH1A1MEN1KMT2A
SCHEMBL5424646 0.69 HPGD (0.47) HPGDTDP1ALDH1A1LMNAHSP90AA1
SCHEMBL11728283 0.69 ALDH1A1 (0.46) HPGDTDP1ALDH1A1LMNAHSP90AA1
SCHEMBL5419503 0.69 HPGD (0.47) HPGDTDP1ALDH1A1LMNAHSP90AA1
SCHEMBL21282929 0.67 TTR (0.47) RAF1PKMYT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 — — US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 — — US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 — — EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 — — US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 — — US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 RAF1 4002/4885HPGD 2964/4885TDP1 4481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback